Biotechnology

Filter

Current filters:

None

Popular Filters

1940 to 1964 of 2471 results

EMA has most advanced policies on conflict of interest issues, says ECA report

11-10-2012

A review by the European Court of Auditors of the management of conflicts of interests in four independent…

BiotechnologyEuropePharmaceuticalRegulation

EMA expects lower rate of generic applications; Issues guidelines on schizophrenia and MS

11-10-2012

In its mid-year report for 2012, the European Medicines Agency's management board yesterday provided…

BiotechnologyEuropeGenericsNeurologicalPharmaceuticalRegulationResearch

Immunomedics' milatuzumab a possible breakthrough for graft-versus-host disease

10-10-2012

US biotech firm Immunomedics (Nasdaq: IMMU), company primarily focused on the development of monoclonal…

BiotechnologyImmunologicalsImmunomedicsmilatuzumabResearch

Health Canada's fast-tracked drug approvals "can put public at risk"

09-10-2012

Drugs streamed into pharmaceutical regulator Health Canada's accelerated review process are more likely…

BiotechnologyNorth AmericaPharmaceuticalRegulation

US nephrologists expect rapid adoption of USA's first biosimilars - epoetin alfa

09-10-2012

More than 60% of surveyed nephrologists in the USA expect to begin prescribing biosimilar epoetin alfa…

BiotechnologyDiabetesGenericsMarkets & MarketingNephrology and Hepatology

Future of pharma R&D requires innovative dosage formulations, industry survey shows

09-10-2012

A survey of 500 pharmaceutical industry influencers reveals that four out of five surveyed (82%) believe…

BiotechnologyCapsugelPharmaceuticalProductionResearch

Mixed results with Eli Lilly Alzheimer's drug solanezumab, but investors pleased

09-10-2012

US pharma major Eli Lilly (NYSE: LLY) yesterday reported detailed results from two Phase III studies…

BiotechnologyEli LillyNeurologicalPharmaceuticalResearchsolanezumab

Strong pharma research is key to bringing in investment

09-10-2012

"Few people disagree that small drug discovery companies are vital to the health of the UK's pharma industry,…

BiotechnologyEuropeFinancialPharmaceuticalResearch

Germany seeks closer partnership with Japan in biopharmaceuticals

08-10-2012

Germany Trade & Invest (GTI) and the Health - Made in Germany initiative will join forces at this year's…

Asia-PacificBiotechnologyEuropeLicensingResearch

Industry and government cooperate to stimulate biotech clinical trials in Italy

08-10-2012

In Italy last week, the Director General of AIFA (Agenzia Italiana del Farmaco) Luca Pani, the president…

BiotechnologyEuropeRegulationResearch

UK's NICE draft guidance backs NHS use of Lucentis in DME

05-10-2012

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE), in new draft guidance…

BiotechnologyEuropeLucentisNovartisOphthalmicsPharmaceuticalPricingRegulation

"Sandoz will be the leading biosimilars company in 2012," says Visiongain

04-10-2012

Sandoz, the generics unit of Swiss drug major Novartis (NVN: VX), will retain its position as the global…

BiotechnologyDr Reddy's LaboratoriesGenericsGlobalHospiraMarkets & MarketingNovartisSandoz

New US bill would provide exclusivity add-on for significant drug combos

04-10-2012

Legislation co-sponsored in the USA by Representatives Brian Bilbray (Republican, California), Carolyn…

BiotechnologyLegalNorth AmericaPharmaceuticalRegulation

New Canadian rare disease strategy welcomed as offering hope and solutions for patients

04-10-2012

The Canadian government this week announced a new national framework to improve access to "orphan drugs"…

BiotechnologyNorth AmericaPharmaceuticalRare diseasesRegulationResearch

European Commission looks for feedback on pediatric regulation experience

04-10-2012

The European Commission has launched a public consultation on the experience gained with the paediatric…

BiotechnologyEuropePharmaceuticalRegulationResearch

Sarepta rockets as eteplirsen seen to significantly benefit Duchenne patients

04-10-2012

US RNA-based drug developer Sarepta Therapeutics (Nasdaq: SRPT) saw its shares rocket 200% to $44.93…

BiotechnologyeteplirsenPharmaceuticalRare diseasesResearchSarepta Therapeutics

Celgene's Abraxane meets main goal in melanoma trial; reviews nanomedicines

04-10-2012

Celgene International Sarl, a subsidiary of the USA's Celgene Corp (Nasdaq: CELG) has announced results…

AbraxaneBiotechnologyCelgeneOncologyPharmaceuticalResearch

1940 to 1964 of 2471 results

Back to top